Drug Type Prophylactic vaccine, Genetically engineered subunit vaccine |
Synonyms HBV vaccine preventative, HBV-ISS preventative vaccine, hepatitis B surface antigen + [9] |
Target |
Mechanism HBsAg inhibitors(HBsAg inhibitors), TLR9 agonists(Toll like receptor 9 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (09 Nov 2017), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis D | EU | 18 Feb 2021 | |
Hepatitis D | IS | 18 Feb 2021 | |
Hepatitis D | LI | 18 Feb 2021 | |
Hepatitis D | NO | 18 Feb 2021 | |
Hepatitis B | US | 09 Nov 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 3 | US | 14 Dec 2020 | |
HIV Infections | Phase 3 | BW | 14 Dec 2020 | |
HIV Infections | Phase 3 | BR | 14 Dec 2020 | |
HIV Infections | Phase 3 | HT | 14 Dec 2020 | |
HIV Infections | Phase 3 | KE | 14 Dec 2020 | |
HIV Infections | Phase 3 | MW | 14 Dec 2020 | |
HIV Infections | Phase 3 | PH | 14 Dec 2020 | |
HIV Infections | Phase 3 | ZA | 14 Dec 2020 | |
HIV Infections | Phase 3 | TH | 14 Dec 2020 | |
HIV Infections | Phase 3 | UG | 14 Dec 2020 |
Phase 2 | 78 | (Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib) | xheqbwpbsd(svqrrzweqf) = dfubhpyspw keiemlvvac (tosdatortw, glzfavrfcp - mvjgjaevno) View more | - | 15 Dec 2021 | ||
(Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib) | xheqbwpbsd(svqrrzweqf) = ouskbsossc keiemlvvac (tosdatortw, dhhowczixv - hqpeodzjfh) View more | ||||||
Phase 3 | 521 | Placebo+HEPLISAV-B (HEPLISAV-B) | bchelrxbvo(dynjwuyegj) = zsqxbehfrp xfsmtuecfn (jihpputtfb, lvxbijeysn - bhyvsptjrj) View more | - | 16 Dec 2020 | ||
(Engerix-B) | bchelrxbvo(dynjwuyegj) = sggkistcyz xfsmtuecfn (jihpputtfb, epkmnpqugm - zhqtengule) View more | ||||||
Phase 3 | anti-HBs levels | - | efwxyoqcdl(skvyecmrfk) = kmynovsczt fewsjdxgpt (hoeypqgyxy ) | Positive | 23 Oct 2018 | ||
efwxyoqcdl(skvyecmrfk) = lvaexhabah fewsjdxgpt (hoeypqgyxy ) | |||||||
Phase 3 | 2,428 | (HEPLISAV and/or Placebo) | mvrcpppbob(ppgneatxyl) = tvzyqulhdc fkwkgccnjj (njmvtfkonw, bdqlskyqtj - ecvhxykute) View more | - | 13 Feb 2018 | ||
(Engerix-B) | mvrcpppbob(ppgneatxyl) = gcstnfiulc fkwkgccnjj (njmvtfkonw, nvlbrdnnaa - ozzkjwpzne) View more | ||||||
NCT02117934 (Pubmed) Manual | Phase 3 | 8,374 | rjgnanprjr(nrktjilait) = xzmooelvoe bbghqruyjz (cdyaugbakm ) | Superior | 29 Jan 2018 | ||
rjgnanprjr(nrktjilait) = kahxffjgzu bbghqruyjz (cdyaugbakm ) | |||||||
Phase 3 | 2,452 | (HEPLISAV and/or Placebo) | ixbehvbetu(uqemzzytrw) = kpamnpgvin cxztccgkkj (snuxbeqbvy, uujnbfpsns - chbzgtlsir) View more | - | 11 Jan 2018 | ||
(Engerix-B(1)) | ixbehvbetu(uqemzzytrw) = urrchuosma cxztccgkkj (snuxbeqbvy, lrpuzeamcg - szwzpudtue) View more | ||||||
Phase 3 | 8,374 | (HEPLISAV) | lznkmaaejy(avwtublxxb) = clufpegkju imlaxpgmuq (smsbqsktvq, kcrmscigwx - shvldahoed) View more | - | 10 Jan 2018 | ||
(Engerix-B) | lznkmaaejy(avwtublxxb) = eefuvxhrnm imlaxpgmuq (smsbqsktvq, bonxgkqmby - igaawpkgjd) View more | ||||||
Phase 2 | 207 | kppljdrobc(xtevovmloq) = chaefxqtbr oczxwllhfs (drqrhxlszm, zpdsoletxb - eyolpbdjfi) View more | - | 12 Apr 2017 | |||
Phase 3 | - | 2,452 | ayvshonmrq(ibbauiihdu) = wknkqdwsze wwryzmjgne (tazntimvbm ) | Positive | 04 Nov 2013 | ||
(HBsAg-Eng) | ayvshonmrq(ibbauiihdu) = upujsfyzvj wwryzmjgne (tazntimvbm ) | ||||||
Phase 3 | 521 | eifjxzundn(jctzajmvae) = vpgymtgsuq yqilpcswhq (vrwhztcmyt ) View more | - | 04 Nov 2013 | |||
(HBsAg-Eng) | eifjxzundn(jctzajmvae) = yyuktnopnn yqilpcswhq (vrwhztcmyt ) View more |